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Abstract
Although much progress has been made in identifying genetic defects associated with mitochondrial diseases, the protein
expression patterns of most disorders are poorly understood. Here we use immunochemical techniques to describe subunit
 . expression patterns of respiratory chain enzyme complexes II succinate dehydrogenase: SD and IV cytochrome c oxidase:
.  .COX in cultured cells lacking mtDNA Rho0 cells derived either chemically by exposure of normal cells to ethidium
bromide, or genetically in cells derived from a patient with mtDNA depletion syndrome. Both control cells and early
passage patient-derived cells express a normal complement of SD and COX subunit proteins. Ethidium bromide treatment
of normal cells and in vitro cell proliferation of patient-derived cells caused both populations to acquire identical Rho0
phenotypes. As expected, they lack mtDNA-encoded subunits COX-I and COX-II. In contrast, nDNA-encoded subunits are
 .  .affected differentially, with some COX-VIc lacking and others COX-IV, COX-Va, SD 30 and SD 70 maintained at
somewhat reduced levels. We suggest that the differential stability of nDNA-encoded subunits in the absence of intact
enzyme complexes is due to the ability of some, but not all, subunits to associate as partial complexes in the absence of
mtDNA-encoded subunits. q 1997 Elsevier Science B.V.
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1. Introduction
Mitochondria are the site of oxidative phosphoryla-
 .tion OXPHOS , a process by which a transmem-
brane proton gradient formed by oxidation–reduction
reactions of the four electron transfer complexes of
 .the respiratory chain complexes I–IV is used by an
 .ATP synthase complex V to generate ATP. The
OXPHOS system is unusual in that it has a dual
genetic origin. Thus, complexes I, III, IV and V are
 .composed of both nuclear DNA nDNA -encoded
 .and mitochondrial DNA mtDNA -encoded subunits,
whereas complex II is made entirely of nDNA-en-
w xcoded subunits 1 . Due to their dual genetic control
and the large number of subunit proteins 13
mtDNA-encoded proteins and more than 80 nDNA-
.encoded proteins , biogenesis and assembly of the
OXPHOS system is complicated. In addition, the
various enzyme complexes are subject to develop-
mental and tissue-specific regulation, and respond
w xrapidly to changes in physiological conditions 2,3 .
Respiratory chain and ATPase deficits are now
known to have profound adverse effects on a variety
of cellular and tissue functions, causing a wide range
of complex clinical phenotypes. The incidence of
inherited mitochondrial diseases of energy utilization
w xis estimated to be about 1 in 5000 4 , and it has been
suggested that a much larger population may be
affected when somatic genetic defects, such as
mtDNA mutation and deletions accompanying nor-
w xmal aging, are considered 2,4 . Most of these dis-
eases involve alterations in mitochon-drial respiratory
chain proteins, and many involve complex IV cyto-
. w xchrome c oxidase: COX 5,6 .
Diseases associated with defects in the human
mitochondrial respiratory chain are an extremely het-
erogeneous set of disorders with variable penetrance
and inheritance patterns that can have either tissue-
w xspecific or multi-tissue effects 2,4–9 . Thus, whereas
inherited mitochondrial diseases such as fatal infan-
tile myopathy due to COX deficiency have an early
onset and a severe, invariably fatal phenotype, other
disorders such as Leber’s hereditary optic neuropathy
 .LHON exhibit a later onset with variable penetra-
w xtion 2,4–9 . The clinical phenotype depends on fac-
tors such as whether nDNA or mtDNA-encoded genes
are affected directly, on patterns of mtDNA hetero-
plasmy, and on the energy requirements of the af-
fected tissues.
Although specific genetic defects such as mtDNA
mutations and deletions, and nDNA mutations have
been associated with some mitochondrial diseases,
most disorders remain uncharacterized at the molecu-
lar level. In particular, the molecular expression of
these diseases, i.e. the subunit protein expression
patterns in affected complexes responsible for patho-
logical conditions, remains largely unknown. Direct
analysis of protein expression patterns is necessary
even when specific genetic defects are known be-
cause the effects of such defects are not always
readily predicted. For example, point mutations or
deletions in mtDNA-encoded tRNAs can be expected
to affect individual proteins differentially, depending
on codon usage in individual genes. In addition,
mtDNA defects are often heteroplasmic, and cells of
affected individuals may contain variable mixtures of
defective and wild type mtDNA. A mtDNA defect
may be expressed clinically only when the propor-
tion, or perhaps the absolute amount, of normal
w xmtDNA falls below a threshold level 10–12 . Fi-
nally, genetic defects in proteins encoded by mtDNA
or nDNA can have secondary effects on proteins that
normally associate or otherwise interact with the
 . w xdirectly affected protein s 13 .
To better understand mitochondrial diseases, and
in turn to utilize these defects to better understand
normal OXPHOS assembly and regulation, we have
begun to describe altered expression patterns of OX-
PHOS subunit proteins in specific mitochondrial dis-
orders. Previously, we described characteristic alter-
ations in the expression of COX subunit proteins in a
patient with chronic progressive external ophthalmo-
 .plegia CPEO harboring a heteroplasmic mtDNA
w xdeletion 13 . The subunit expression pattern was
determined by immunochemical analysis of patient
skeletal muscle tissue sections, using a battery of
subunit specific anti-COX monoclonal antibodies
w xmade by us 13–15 . In the present study of COX
deficiency, we extend this analysis to include a de-
scription of complex II succinate dehydrogenase:
.SD subunits as well as COX subunits, and use
cultured cells to facilitate single cell analysis and
develop a renewable source of experimental material.
Normal cultured fibroblasts were compared to
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 .Rho0 fibroblasts cells lacking mtDNA of two dis-
tinct origins. Thus, mtDNA was eliminated either
genetically in cells derived from a patient with
mtDNA depletion syndrome or chemically by treat-
ment of normal cells with ethidium bromide. We
show that both types of Rho0 cells exhibit the same
characteristic altered subunit expression pattern, and
that this pattern reveals not only direct effects on
mtDNA-encoded subunits, but also indirect non-
.genetic effects on certain nDNA-encoded subunits.
These observations provide insight into subunit–sub-
unit interactions involved in assembly of mitochon-
drial enzyme complexes and underscore the necessity
of characterizing protein expression patterns to fully
understand mitochondrial diseases.
2. Materials and methods
2.1. Patient a5065
This female patient was born 6 lb 7 oz to a 23-year
old African-American woman. Because of lethargy
and poor feeding she was kept in a neonatal intensive
care for one week. At one month of age she was
re-admitted to hospital for failure to thrive, hypoto-
nia, and possible blindness. She was found to have a
persistently elevated blood lactate, pulmonary hyper-
tension, ventricular hypertrophy, and a cardiac con-
duction defect. Her liver was enlarged, she had mild
generalized hypotonia but deep tendon reflexes were
present. She had intermittent eye rotation movements
and her respiratory efforts were poor. Urine organic
acids showed elevated lactic, fumaric, malic, 2-hy-
droxybutyric, 2-ethyl-3 hydroxypropionic and 2-oxo-
gluta-rate. Blood ammonia level was normal. Blood
lactate was 13 mM with a blood pyruvate of 0.07 mM
giving a lactate to pyruvate ratio of 115 : 1, which is
far above the control range for blood lactate to
 .pyruvate ratios of 12–25 : 1 n s 17 . Her condi-
tioned worsened and weakness caused her to become
ventilator dependent. She developed enterococcal
sepsis and died from septic shock at 12 weeks of age.
2.2. a5065 fibroblasts
Fibroblasts were established from a skin biopsy of
patient a5065 after informed parental consent. Infor-
mation regarding the number of early cell population
doublings was not available, so population doubling
level 0 was defined as the initial set of cultures
obtained by us. Cells were subcultured by trypsiniza-
tion when confluent and seeded at 1 : 2 or 1 : 4 splits.
The cells were grown in High Glucose Dulbecco’s
Modified Eagles medium supplemented with 10%
fetal calf serum, 50 mgrml uridine, 110 mgrml pyru-
 .vate, and 10 mM Hepes buffer permissive medium .
No antibiotics were used. Selective growth medium
 .selective medium was prepared as above except that
5% dialyzed fetal calf serum was used and the
medium lacked pyruvate and uridine.
2.3. MRC5 control fibroblasts
MRC5 fibroblasts were obtained from the Ameri-
can Type Culture Collection. The population dou-
 .bling PD level of the cells was PD s 25 when
received. The total PD level of MRC5 cells used in
the present study ranged from 30 to 45. There were
no detectable differences in the growth rates or respi-
ratory chain protein expression patterns in this range
of PDs.
2.4. MRC5-Rho0 fibroblasts
Rho0-MRC5 fibroblasts were derived by culturing
 .MRC5 fibroblasts PD s 28 in permissive medium
supplemented with ethidium bromide at 50 ngrml.
All experiments reported here were done using Rho0-
MRC5 cells grown continuously in the presence of
ethidium bromide for between 12 to 22 PDs.
2.5. Enzyme acti˝ity measurements
Activities of respiratory chain components were
measured from whole cell extracts as follows: COX
w xby the methods of DiMauro et al. 16 , succinate
cytochrome c reductase by following the reduction of
 .cytochrome c complexes II q III by the method of
w xFischer et al. 17 , and citrate synthase by the method
w xof Shepherd and Garland 18 .
2.6. Anti-complex II monoclonal antibodies
RBFrDnJ mice were immunized with purified
bovine complex II emulsified in complete Freund’s
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adjuvant, boosted twice at monthly intervals with
antigen in incomplete Freund’s adjuvant all intra-
.peritoneal at 50 mg per mouse per injection , and
finally with 50 mg antigen in saline intravenously.
Hybridomas were generated using immune spleno-
cytes and FOX-NY myelomas as described previ-
w xously 19 . The resulting monoclonal antibodies were
 .screened sequentially for ability to: 1 bind specifi-
cally to pure bovine complex II adsorbed to
 .polystyrene, 2 recognize a single band in western
blotted bovine complex II either the 30 kD Fe–S
.  .protein or the 70 kD flavoprotein , 3 recognize a
single 30 or 70 kD band in western blots of whole
 .cell human fibroblast extracts, and 4 bind specifi-
cally to mitochondria in fixed cultured human fibrob-
lasts. An anti-30 kD Fe–S protein monoclonal anti-
 .body 21A11-AE7: IgG2Ak and an anti-70 kD
flavoprotein monoclonal antibody 2E3-GC12-FB2-
.AE2: IgG1k met these requirements and were used
here.
2.7. Immunohistochemistry
Cells were grown on acid-cleaned glass slides and
used before they became confluent. Cultures were
rinsed with warm Hanks-Balanced Salt Solution con-
 .taining 10 mM Hepes HH , fixed for 20 min @ 48C
in fresh 4% paraformaldehyde in HH, and then for
60 min at 48C in fresh 4% paraformaldehyde in 0.1 M
Na-Borate, pH 11. Fixed cultures were washed exten-
sively with calcium and magnesium free Dulbecco’s
 .phosphate buffered saline CMF-PBS , permeabilized
by treatment for 15 min in acetone at y208C, and
then washed extensively with CMF-PBS. Non-
specific binding was blocked by treatment for 1 h in
 .10% normal goat serum NGS in CMF-PBS at room
temperature 508C for anti-COX-IV MAb 10G8-D12-
.C12 . The cells were then incubated in primary anti-
bodies overnight at 48C in 10% NGS. After being
washed extensively with CMF-PBS, labeled cells
were incubated for 2 h with goat anti-mouse IgG Hq
. L -Texas Red conjugate Southern Biotechnology
.Associates at 20 mgrml in 10% NGS with 10 mgrml
 .Hoechst dye 33258 to stain nuclei , washed well,
mounted in Tris-buffered glycerol 90% glycerol,
15 mM NaCl, 1 mgrml p-phenylene diamine, 50 mM
.Tris, pH 9 and viewed.
The anti-COX monoclonal antibodies used here
w xhave been described previously 13–15 and included
 .  .anti-COX-I 1D6-E1-A8 , anti-COX-II 12C4-F12 ,
 .anti-COX-IV 10G8-D12-C12 , and anti-COX-VIc
 .3G5-F7-G3 . They were used as purified IgGs di-
luted to 5 mgrml in 10% NGS. The anti-SD 30 kD
 .Fe–S protein 21A11-AE7 and anti-SD 70 kD flavo-
 .protein 2E3-GC12-FB2-AE2 monoclonal antibodies
described above were used as neat cell culture super-
natants.
The mitochondrial-specific dye MitoTracker-
 .CMTMRos aM-7510, Molecular Probes was ap-
plied at 0.1 mM in culture medium to live cells for
45 min at 378C. The cultures were then washed 3
times for 10 min with warm culture medium, rinsed
twice with warm HH, and fixed as above.
2.8. Western blot analysis of mitochondrial proteins
Western blots were done using either whole cell
extracts or mitochondrial pellets as samples. In either
 .case, recently confluent 1–2 days cell cultures were
rinsed with CMF-PBS, dissociated with 0.25% trypsin
in CMF-PBS @ 378C, mixed with an equal volume
of complete medium containing 10% FCS, and col-
lected by centrifugation.
Whole cell extracts were prepared by rinsing the
trypsinized cells with CMF-PBS, then with CMF-PBS
containing protease inhibitors 0.5 mgrml Leupeptin,
.0.5 mgrml Pepstatin and 1 mM PMSF . Cell pellets
were then solubilized for 30 min at 5 = 106 cellsrml
in CMF-PBS containing the above protease inhibitors
plus 1.5% lauryl maltoside at 48C, centrifuged for
20 min at 16,600 = g, and the supernatants saved.
For mitochondrial pellets, trypsinized cells were
rinsed three times with CMF-PBS and then frozen at
y858C. Cell pellets were thawed in homogenization
buffer 1 mM EDTA, 0.25 M Sucrose, 10 mM Tris,
. pH 7.4 and protease inhibitors 0.5 mgrml Leu-
.peptin, 0.5 mgrml Pepstatin and 1 mM PMSF , and
homogenized with a motorized pestle. The cell ho-
mogenate was centrifuged 10 min at 1500 = g and
the supernatant saved. The pellet was repeatedly two
.times homogenized as above, the post-nuclear super-
natants combined and centrifuged again 10 min at
1500 = g. The post-nuclear supernatant was then
centrifuged for 12 min at 10,000 = g, the mitochon-
drial pellet saved, suspended in homogenization buffer
and then centrifuged again for 12 min at 10,000 = g.
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The final mitochondrial pellet was suspended in a
small volume of homogenization buffer and stored
frozen.
Equivalent amounts of protein, determined with
the Pierce bicinchoninic acid kit, were separated on
w xpolyacrylamide gels as previously described 15 , ex-
cept that 10–20% gradient gels lacking urea were
used for all subunits, and then transferred elec-
trophoretically to 0.2 mm nitrocellulose membranes
in CAPS transfer buffer 10% methanol in 10 mM
w x .3- cyclohexylamino -1-propanesulfonic acid, pH 11
on ice. The blots were blocked with 5% non-fat dried
milk powder in CMF-PBS, incubated overnight at
48C in primary antibodies diluted in 5% milk CMF-
PBS, washed with 0.05% Tween in CMF-PBS, incu-
bated for 1 h in horse radish peroxidase conjugated
 .goat anti-mouse IgGqM HqL at 0.2 mgrml
 .Jackson Immuno Research in 5% milk CMF-PBS,
washed with 0.05% Tween in CMF-PBS, rinsed with
CMF-PBS, incubated 1 min in Dupont Renaissance
chemiluminescent reagent and exposed to X-ray film
which was then developed and analyzed.
Purified monoclonal antibodies were used as fol-
 .lows: anti-COX-I 1D6-E1-A8 at 2 mgrml, anti-
 .COX-II 12C4-F12 at 1 mgrml, anti-COX-IV
 .10G8-D12-C12 at 1 mgrml, and anti-COX-VIc
 .3G5-F7-G3 at 4 mgrml. The remaining monoclonal
antibodies were used as hybridoma cell culture super-
 .natants as follows: anti-COX-Va 6E9-B12-D5 at
 .1 : 20 ratio, anti-SD 30 kD Fe–S protein 21A11-AE7
at 1 : 10 ratio, and anti-SD 70 kD flavoprotein 2E3-
.GC12-FB2-AE2 at 1 : 400 ratio.
2.9. Southern blot analysis of mitochondrial DNA
 .Recently confluent 1–2 days cell cultures were
rinsed with CMF-PBS, dissociated with 0.25% trypsin
in CMF-PBS @ 378C, mixed with an equal volume
of complete medium containing 10% FCS, and col-
lected by centrifugation, washed with CMF-PBS and
Fig. 1. Electron microscopy shows that the mitochondria of cultured fibroblasts lacking mtDNA MRC5-Rho0 fibroblasts and
.late-passage mtDNA depleted patient a5065 fibroblasts are swollen and fragmented, with poorly developed, sparse cristae in comparison
 .to the mitochondria of normal cells control MRC5 fibroblasts . Arrows indicate cristae within mitochondria. Note that all mitochondria
have distinct inner and outer membranes, but that cristae are sparse within the swollen mitochondria of both MRC5-Rho0 and a5065
 .cells Bars s 0.1 mm .
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Fig. 2. mtDNA is reduced to near background levels in both
 .MRC5-Rho0 grown for 16 PD in ethidium bromide and late
 .passage 5065 cells 5065-02-16:PD 18 . In contrast, early pas-
 .sage 5065 cells 5065-02-05:PD 7 contain low but detectable
levels of mtDNA. Note that due to difficulties in obtaining early
passage samples, much less DNA was loaded on the early
 .passage 5065 lane 0.6 mg than on the Control MRC5, late-pas-
 .sage 5065, or MRC5-Rho0 lanes 3.0 mg . Whole cell DNA was
digested with P˝uII, blotted as described in the Section 2 and
w 32 xprobed simultaneously with two a- P dCTP labeled probes: a
5.8 kb fragment of the nuclear gene encoding 18S rRNA, and the
entire mtDNA sequence obtained by long-range PCR.
then frozen at y858C. Whole cell DNA was ex-
 .tracted with the Nucleon kit Scotlab , and then
similar amounts were digested with P˝uII to lin-
earize mtDNA, electrophoresed through a 0.8%
agarose gel and transferred to Hybond-N membrane
 .Amersham as recommended by the supplier. Blots
were then hybridized with two probes simultane-
ously: a 5.8 kb fragment of the nDNA gene encoding
 .18S rRNA courtesy of Dr. I.J. Holt and the entire
mtDNA sequence obtained by long-range PCR
 .courtesy of Dr. J.C. Blake . Probes were labeled
w 32 xwith a- P dCTP using the Rediprime random primer
 .labeling system Amersham . Blots were prehy-
bridized, hybridized and washed as recommended by




Many mitochondrial deficiencies lead to variable
levels of the different electron transfer complexes and
ATP synthase of the OXPHOS system. One extreme
example is mtDNA depletion syndrome, in which
mtDNA is lacking from cells in certain tissues. Such
a condition is equivalent to experimentally-derived
Rho0 cells. Therefore, we initially examined Rho0
cells created by chronic exposure to ethidium bro-
mide to establish a reference subunit protein expres-
sion pattern for this condition and to begin to under-
stand the extent of mitochondrial assembly when
mitochondrial gene products are absent.
Fig. 1 compares the morphology of normal and
Rho0 cell mitochondria by electron microscopy. Rho0
mitochondria are swollen and fragmented, with poorly
developed, loose cristae. Southern blots confirmed
 .that these cells contain no mtDNA Fig. 2 . As
Table 1
Enzyme Normal skin fibroblasts Normal MRC5 fibroblasts MRC5-Rho0 fibroblasts 5065 PD 17 fibroblasts
 .  .  .Cytochrome c oxidase 5.49 " 0.82 6 4.0 0.31 " 0.13 6 0.71 " 0.28 6
nmolrmgrmin
 .  .  .Succinate cytochrome 6.67 " 1.2 3 7.4 0.09 " 0.09 6 0.00 6
c reductase nmolrmgrmin
 .  .  .Citrate synthase 23.8 " 0.9 5 24.9 98.5 " 3.6 6 46.4 " 1.3 6
nmolrmgrmin
 .MRC5-Rho0 and mtDNA-depleted 5065 cells late passage PD 17: subculture 5065-02-15 contain little or no activity of COX and
Succinate cytochrome c reductase. This is consistent with the genetic origin of these enzyme complexes, i.e. they contain mtDNA-en-
coded subunit proteins. In contrast, both cell populations contain elevated levels of citrate synthase, a mitochondrial enzyme complex
encoded entirely by nDNA.
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Fig. 3.
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 .Fig. 3. A and B . Early passage 5065 cells are a mosaic cell population of Rho0-like cells and relatively normal cells. All nuclei in Fig.
 .3 A are identified with asterisks to emphasize the cellular mosaicism revealed with antibodies to COX-I, COX-II and COX-VIc. Both
 .MRC5-Rho0 and Rho0-like 5065 cells have distorted mitochondria upper panel of 3B that lack detectable levels of mtDNA-encoded
 . subunits COX-I and COX-II upper and middle panels of 3A . Although these cells also lack nDNA-encoded COX-VIc lower panel of
.  .  .3A , they do contain nDNA-encoded COX-IV lower panel of 3B . Control MRC5, early-passage patient 5065 5065-02-04: PD 6 , and
 .MRC5-Rho0 grown for 19 PD in ethidium bromide cells were fixed and labeled with monoclonal antibodies monospecific for each of
 .the indicated subunits. ‘‘Mito’’ refers to late-passage pateint 5065 cells PD 15: 5065-02-13 labeled with the mitochondrial-specific dye
 .MitoTracker-CMTMR see Section 2 .
expected, activities of succinate cytochrome c reduc-
 .tase complex II and III and COX were essentially
nil because of a lack of mtDNA-encoded cytochrome
 .b, COX-I, COX-II or COX-III Table 1 . In contrast,
citrate synthase, a mitochondrial enzyme complex
encoded solely by nDNA, is up-regulated signifi-
 .cantly in these cells Table 1
Immunochemical techniques can be used to char-
acterize expression of individual respiratory chain
subunit proteins. To this end, we have developed a
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set of MAbs that are absolutely specific for individ-
w xual subunits of COX 13–15 . These antibodies each
react only with a single band in western blots of
whole cell preparations. Many can be used in im-
munohistochemistry and can therefore also provide
information on COX composition of single cells.
 .Fig. 3. A and B shows staining of COX-I, COX-
II, COX-IV, COX-VIc, and MitoTracker a mito-
.  .chondrion-specific dye in Rho0 and normal MRC5
cultured skin cells. As expected, mtDNA-encoded
subunits COX-I and COX-II are missing in Rho0
cells. In contrast, nDNA-encoded subunits are af-
fected differentially in the Rho0 cells. COX-IV is
present at slightly reduced levels while COX-VIc is
not detected at all. These results are confirmed by
Fig. 4. MRC5-Rho0 cells lack detectable levels of mtDNA-en-
coded subunits COX-I and COX-II. They also lack nDNA-en-
coded subunit COX-VIc, but do contain the nDNA-encoded
subunits COX-IV and COX-Va. Mitochondrial protein was loaded
at 8 mgrlane for MRC5 cells and at 15mgrlane for MRC5-Rho0
 .cells grown for 24 PD in ethidium bromide . Western blots were
reacted with mixtures of monoclonal antibodies monospecific for
each of the indicated subunits.
Fig. 5. MRC5-Rho0 cells contain the nDNA-encoded 30 kD and
70 kD subunits of succinate dehydrogenase. Panel A: Mitochon-
drial proteins were loaded at 4 mgrlane for both MRC5 cells and
 .MRC5-Rho0 cells grown for 24 PD in ethidium bromide . Panel
B: Mitochondrial proteins were loaded at 28 mgrlane for both
MRC5 cells and MRC5-Rho0 cells grown for 18 PD in ethidium
.bromide . Western blots were reacted with monoclonal antibodies
monospecific for each of the indicated subunits.
western blots as shown in Fig. 4. Although the
anti-COX-Va used here does not work in immunohis-
tochemistry under these conditions, Western blots
clearly show that COX-Va is also present in both
 .normal and Rho0 cells Fig. 4 . Finally, Rho0 mito-
chondria visualized with MitoTracker or anti-COX-IV
 .have a distorted, fragmented appearance Fig. 3 that
is consistent with mitochondrial morphology ob-
 .served by electron microscopy Fig. 1 .
To expand our analysis of OXPHOS subunits, we
are making additional MAbs specific for selected
polypeptides of other electron transfer complexes.
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Here we use two new anti-succinate dehydrogenase
 .complex II MAbs that meet our criteria, i.e. each
MAb reacts with the native protein, recognizes a
single band in western blots of whole cell protein or
 .mitochondria Fig. 5 , and can be used in immunohis-
 .tochemistry Fig. 6 . One MAb is specific for the
small 30 kD Fe–S protein subunit while the other is
specific for the large 70 kD flavoprotein subunit.
These and all other subunits of complex II are en-
w x  .coded by nDNA 1 . The Western blot Fig. 5 and
 .immunohistochemical Fig. 6 data show that these
two major subunits of complex II are expressed at
 . essentially normal SD 70 or slightly reduced SD
.30 levels in the mitochondria of Rho0 cells.
3.2. Patient a5065
We have begun to screen skin fibroblasts from
OXPHOS deficient patients to characterize subunit
expression patterns in mitochondrial disease and
Fig. 6. All MRC5-Rho0 and 5065 cells contain nDNA-encoded SD 30 and SD 70 subunits. Control MRC5, patient 5065 5065-03-05: PD
.  .8 , and MRC5-Rho0 grown for 13 PD in ethidium bromide cells were fixed and labeled with monoclonal antibodies monospecific for
the indicated subunits.
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Fig. 7. Patient 5065 cells rapidly acquire a Rho0-like phenotype
as they proliferate in cell culture. 5065-03 fibroblasts were grown
in standard medium and samples were fixed after a total of 3, 7
and 11 PD. The fixed cultures were then labeled with monoclonal
antibodies specific for the indicated subunits of cytochrome
oxidase and individual cells were scored for immunoreactivity.
 .See Section 2 .
identify useful phenotypes for further study. Patient
a5065 was identified in this screen and shown to
exhibit a dynamic mtDNA depletion syndrome. These
mtDNA-depleted fibroblasts therefore provide a ge-
Fig. 8. 5065 fibroblasts acquire a Rho0-like phenotype as they
proliferate in culture. Note that mtDNA-encoded COX-I and
 .COX-II are progressively extinguished panel A , while nDNA-
 .  .encoded COX-IV, COX-Va panel A , SD 70 panel B and SD
 .30 panel C are maintained. nDNA-encoded COX-VIc is also
 .extinguished during this time not shown . Panel A: Whole cell
extract proteins were loaded at 12 mgrlane for control MRC5,
 .and 28 mgrlane for early passage 5065 5065-02-05:PD 7 and
 .late-passage 5065 5065-02-14: PD 16 cells. Panel B: Whole cell
extract proteins were loaded at 28 mgrlane for both MRC5 cells
 .and 5065 cells 5065-02-14:PD 16 . Panel C: Mitochondrial
proteins were loaded at 28 mgrlane for both MRC5 cells and
 .5065 cells 5065-02-12:PD 14 . Western blots were reacted with
mixtures of monoclonal antibodies monospecific for each of the
indicated subunits.
netically-derived counterpart to the ethidium bro-
mide-induced Rho0 cells described above.
Initial immunohistochemical analysis of early pas-
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sage a5065 fibroblasts with subunit-specific antibod-
ies revealed a mosaic cell population consisting of
Rho0-like cells and apparently unaffected cells Fig.
.3 . Like the ethidium bromide-induced Rho0 cells
described above, Rho0-like a5065 cells do not ex-
press detectable levels of mtDNA encoded subunits
COX-I or COX-II, nor of nDNA encoded subunit
COX-VIc. They do however, express nDNA encoded
 .subunit COX-IV Fig. 3 , as well as the nDNA-en-
coded SD 30 kD Fe–S and SD 70 kD flavoproteins
 .Fig. 6 .
When a5065 cells were grown through many
passages to obtain large amounts of protein, we
observed that most of the apparently normal early
passage cells converted rapidly to a Rho0-like pheno-
type. These results were quantitated by immunohisto-
 .chemistry Fig. 7 and confirmed by Western blots of
both intermediate passage and late-passage cells Fig.
.8 . The steady-state levels of nDNA-encoded COX-
IV, COX-Va, SD 30, although reduced, remained
relatively high long after both mtDNA-encoded
COX-I, COX-II and nDNA-encoded COX-VIc be-
came undetectable. SD 70 steady-state levels ap-
peared to be unaffected in Rho0-like 5065 cells.
Southern blotting confirmed that early passage mo-
saic a5065 cell populations contained reduced
amounts of mtDNA, while late-passage Rho0-like
 .a5065 cells lacked mtDNA Fig. 2 . The residual
mtDNA in early-passage a5065 cells is of normal
length, indicating that mtDNA depletion and not
large scale deletions account for the observed reduc-
tion. Respiratory chain enzyme activity measure-
ments of late-passage mtDNA depleted a5065 cells
also confirmed the absence of mtDNA encoded pro-
 .teins Table 1 . Like Rho0 cells, mtDNA-depleted
late passage a5065 cells lack almost all COX and
succinate cytochrome c reductase activities, but show
elevated levels of nDNA-encoded mitochondrial cit-
rate synthase. As described above, these alterations
can be explained by the absence of mtDNA-encoded
proteins.
Like Rho0 cells, mitochondria of late-passage
a5065 cells exhibit an abnormal morphology as
viewed by both light and electron microscopy Figs.
.1 and 3 . Both sets of mitochondria appear swollen
and fragmented and have sparse poorly developed
cristae.
Finally, the nutritional requirements of Rho0-
MRC5 and late-passage a5065 cells are similar, and
differ from the requirements of control cells. It is
well documented that Rho0 cells require both uridine
w xand pyruvate for continued growth in vitro 20 .
Consistent with these reports, we observed that
whereas control MRC-5 cells grew well in both
 .permissive containing uridine and pyruvate and se-
 .lective lacking uridine and pyruvate media, both
Rho0-MRC5 and late-passage mtDNA-depleted
a5065 cells grew slowly in permissive media and
 .failed to grow in selective media data not shown .
4. Discussion
4.1. Steady-state expression pattern of respiratory
chain proteins in Rho0 cells
 .Here we compare complex II SD and complex
 .IV COX subunit composition in wild type fibrob-
lasts and Rho0 fibroblasts derived chemically by
. treatment with ethidium bromide or genetically from
.a patient with mitochondrial depletion syndrome .
Subunit steady-state expression levels were deter-
mined by immunohistochemistry and western blot-
ting. It is important to note that all MAbs used here
are absolutely specific for single subunits in whole
human cells and that they react with native protein,
denatured protein and aldehyde fixed protein. There-
fore, they can be used to purify native intact solubi-
lized COX, to quantitate COX and SD complexes and
subunits by ELISA or western blot assays, and to
detect COX and SD subunit expression in single cells
and single mitochondria by immunohistochemistry
w x .13–15 , and unpublished observations .
We show that both types of Rho0 cells exhibit the
same characteristic altered subunit expression pattern.
As expected, mtDNA-encoded subunits of COX are
not expressed in Rho0 cells. In contrast, the nDNA-
encoded subunits of COX are affected differentially,
 .with some eliminated COX-VIc and others main-
 .tained COX-IV, COX-Va , albeit at reduced steady-
state levels. Other nDNA-encoded mitochondrial pro-
teins, such as the 70 kD flavoprotein, and the 30 kD
Fe–S protein of Complex II which is encoded solely
.by nDNA are maintained in both cell populations.
Similarly, both Rho0 cell populations maintain high,
even increased, levels of nDNA-encoded citrate syn-
thase enzyme activities.
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These results are consistent with and extend our
previous observations that steady-state levels of vari-
ous nDNA-encoded COX subunits are affected dif-
ferentially by the absence of mtDNA-encoded sub-
w xunits 13 . Other studies of human cells, although
limited to analysis of fewer subunits than reported
here, have also shown that some nDNA-encoded
 .COX subunits, particularly COX-IV continue to be
expressed at relatively high steady-state levels even
in the absence of intact COX in a variety of situa-
w xtions, including Rho0 cells lacking mtDNA 21 , cells
treated chronically with specific inhibitors of mito-
w xchondrial protein synthesis 22 , and patients with
w x w x. w xmtDNA depletion 23–26 , but see 27 , CPEO 13 ,
w xor Kearns–Sayre syndrome 28 . nDNA-encoded
COX subunits are also affected differentially in yeast
cells genetically altered to lack mtDNA-encoded COX
subunits R.A. Capaldi and L. Calevetta, unpublished
.observations . As in the human cells described above,
the yeast counterpart of human COX-IV is main-
tained preferentially in such cells.
As described above, although a subset of nDNA-
encoded COX subunits are preferentially maintained
in Rho0 cells that lack intact COX complexes, even
these relatively stable nDNA-encoded COX subunits
show reduced steady-state levels under Rho0 condi-
tions. Similarly, although significant COX-IV expres-
sion is maintained in OXPHOS deficient fibroblasts
depleted of mtDNA-encoded gene products by long-
term treatment with Doxycycline a specific inhibitor
.of mitochondrial protein synthesis , the steady-state
expression level of this subunit is reduced due to a
w xmarkedly increased turnover rate 29 .
Together, these results suggest that differential
steady-state expression levels of various COX
nDNA-encoded subunits are due at least in part to
differences in protein turnover rates. One explanation
for subunit specific differences can be inferred from
the recently solved X-ray crystalographic structure of
w xCOX 30 . The structure shows that COX-IV and
COX-Va interact, and indicates that they may nucle-
ate or stabilize folding of COX-I. These nDNA-en-
coded subunits may therefore form a stable partial
complex in the absence of mtDNA-encoded subunits
I, II and III, accounting for their preferential expres-
w x .sion in Rho0 cells 13 , present study . In contrast,
the X-ray structure shows that subunits Vb and VIc
interact predominantly with subunits IrIII and II,
respectively. Failure of assembly into an intact com-
plex may therefore increase turnover of Vb and VIc,
resulting in the low steady-state levels observed in
w x .Rho0 cells 13 , present study . This interpretation of
the data leads to the prediction that nDNA-encoded
subunits VIa, VIb and VIIa will also be found lacking
in Rho0 cells. Thus, the X-ray structure shows that
subunits VIa, VIb and VIIa are associated predomi-
nantly with mtDNA-encoded subunits, and in particu-
lar, are not associated with subunits IV andror Va. In
contrast, subunit VIIb, which is associated with sub-
 .units IV and Va as well as subunit II , may show
stable expression even in the absence of an intact
complex.
Although protein–protein interactions, as de-
scribed above, appear to influence the preferential
expression of some COX subunits independent of
COX assembly, differential gene expression may also
play a role. Differences exist in the upstream tran-
scriptional regulatory regions of various COX subunit
w xnDNA-encoded genes 31–34 . As previously noted
w x13 , this is consistent with the idea that subunits such
as COX-IV may have additional functions besides
their role in COX and thus be subject to independent
regulation of expression.
4.2. mtDNA depletion
mtDNA depletion was first described by Moraes et
w xal. in 1991 23 and has now been identified in
w xapproximately 30 patients 24,27,35 . Although rare,
mtDNA depletion has been the subject of consider-
able study because it is one of the few mitochondrial
diseases known to be caused by a defective nuclear
w xgene 35,36 .
The clinical phenotype of mtDNA depletion is
variable, due to the large measure variable tissue
specificity in biochemical expression of the defect
w x23,25,26,38–43 . However, it is generally character-
 .ized by early onset at birth or shortly thereafter ,
muscle weakness, lactic acidosis, liver failure or renal
tubulopathy, and a progressive clinical downhill
w xcourse 23–25,27 .
Biochemically, a definitive diagnosis of mtDNA
depletion is based on measurement of a selective loss
w xof mtDNA compared to nDNA 23–25,27 . Consis-
tent with a depletion of mtDNA, the disease is also
characterized by generalized deficiencies of respira-
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tory chain enzyme complexes that incorporate mtDNA
w xencoded subunits 24,27 , whereas mitochondrial en-
zymes that contain only nDNA-encoded subunits in-
.cluding respiratory chain complex II are unaltered or
w xeven show increased activity 42,43 . Respiratory
chain enzyme activities have been shown to decline
w xin concert with a clinical decline 25,26 . Although a
similar decline in mtDNA content was not observed
in the single patient sampled twice by Tritschler et al.
w x25 , more recently a patient has been described in
which a clinical decline was associated temporally
w xwith active in vivo mtDNA depletion 35 .
Previous immunochemical studies showed that
mtDNA-encoded proteins such as subunit COX-II of
w xcomplex IV 23–25,27 and subunit ND-I of complex
w xI 24,25 are absent from affected tissues of mtDNA-
depleted patients. In contrast, it has been reported
w xrepeatedly that nDNA-encoded COX-IV 23–26 is
expressed in mtDNA-depleted tissues of these pa-
tients note however, a reported loss of COX-IV in
w x.some cases of mtDNA depletion 27 . Similarly,
w xBodnar et al. 37 reported that nDNA-encoded com-
 . plex I 24 and 49 kD proteins and complex II 27 kD
.Fe–S and 70 kD flavoprotein proteins are expressed
in mtDNA-depleted patient-derived fibroblasts, al-
though at variably reduced levels.
Our results confirm and extend these previous
reports by providing a more detailed immunohisto-
chemical examination of respiratory chain protein
expression patterns in both genetically and chemi-
cally derived mtDNA depleted cells. We verify that
mtDNA depleted-fibroblasts lack not only mtDNA-
 .encoded proteins COX-I and COX-II but also a
 .nDNA-encoded mitochondrial protein COX-VIc . In
contrast, other nDNA-encoded mitochondrial proteins
 .COX-IV, COX-Va, SD 30 and SD70 continue to be
expressed long after COX-I, COX-II and COX-VIc
become undetectable. Furthermore, immunohisto-
chemistry of individual cultured cells also allowed us
to detect for the first time cellular mosaicism in a
patient with mtDNA depletion syndrome. Analysis of
the degree of mosaicism over time demonstrated that
mtDNA depletion is progressive and associated with
cellular proliferation. Progressive mtDNA depletion
was confirmed by southern blots of early and late
a5065 cell populations. This report marks the second
case in which progressive mtDNA depletion has been
observed in cultures of patient-derived fibroblasts
w x37 . Similar results will also be reported for my-
w xoblasts from a different patient 35 .
Progressive mtDNA depletion in vitro is most
likely due to active mtDNA depletion within individ-
ual cells and not to the overgrowth of cultures by an
existing subpopulation of mtDNA-depleted cells.
Such overgrowth is unlikely because mtDNA-de-
pleted late passage a5065 cells, like MRC5-Rho0
cells, grow more slowly than normal fibroblasts or
early passage a5065 cells. If mtDNA depletion does
occur on a cellular basis, then the early passage
a5065 cellular mosaicism we observed probably re-
flects the different proliferative histories of individual
cells.
The ability of mtDNA depletion fetuses to develop
to term while harboring such a rapidly progressing
 .defect suggests that the affected gene s is not ex-
pressed until relatively late in development. One
possibility would be a regulator of tissue specific
mtDNA levels that is normally activated after termi-
nal cell differentiation. This would also be consistent
with the tissue specificity commonly reported in
mtDNA depletion patients as described above. Since
tissue variability of expression has also been shown
w xwithin families with mtDNA depletion syndrome 23 ,
this may indicate that the clinically identified
mtDNA-depleted phenotype is always mosaic, as to-
tal body mtDNA depletion would be incompatible
with life.
Further description of subunit protein expression
patterns in these and other altered conditions will
help us better understand the extent of mitochondrial
assembly when specific mitochondrial or nuclear gene
products are absent. Characterization of the molecular
details of mitochondrial diseases will also lead to
improved diagnostic and therapeutic approaches to
these disorders.
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